PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that in BRCA-proficient triple-negative breast cancer (TNBC), PI3K inhibition would resul...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Ibrahim, Yasir H., García-García, Celina, Serra, Violeta, He, Lei, Torres-Lockhart, Kristine, Prat, Aleix, Anton, Pilar, Cozar, Patricia, Guzmán, Marta, Grueso, Judit, Rodríguez, Olga, Calvo, Maria Teresa, Aura, Claudia, Díez, Orland, Rubio, Isabel T., Pérez, José, Rodón, Jordi, Cortés, Javier, Ellisen, Leif W., Scaltriti, Maurizio, Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5125254/
https://ncbi.nlm.nih.gov/pubmed/22915752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0348
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados